Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Cryofocus Medtech (Shanghai) Co's annualizedNet Income for the quarter that ended in Dec. 2025 was HK$-31.71 Mil.
Cryofocus Medtech (Shanghai) Co's average Total Assets over the quarter that ended in Dec. 2025 was HK$163.26 Mil. Therefore, Cryofocus Medtech (Shanghai) Co's annualized ROA % for the quarter that ended in Dec. 2025 was -19.42%.
HKSE:06922'
s ROA % Range Over the Past 10 Years
Min: -184.36 Med: -48.18 Max: -19.34
Current: -19.34
During the past 6 years, Cryofocus Medtech (Shanghai) Co's highest ROA % was -19.34%. The lowest was -184.36%. And the median was -48.18%.
HKSE:06922's ROA % is ranked worse than 74.74% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.76
vs HKSE:06922: -19.34
Cryofocus Medtech (Shanghai) Co (HKSE:06922) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Cryofocus Medtech (Shanghai) Co ROA % Related Terms
Cryofocus Medtech (Shanghai) Co ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cryofocus Medtech (Shanghai) Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryofocus Medtech (Shanghai) Co ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cryofocus Medtech (Shanghai) Co's ROA % distribution charts can be found below:
* The bar in red indicates where Cryofocus Medtech (Shanghai) Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Cryofocus Medtech (Shanghai) Co (HKSE:06922) has a ROA % of -19.42% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Cryofocus Medtech (Shanghai) Co and its competitors. According to the industry distribution chart, Cryofocus Medtech (Shanghai) Co ranks #636 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 74.7%.
Is Cryofocus Medtech (Shanghai) Co's ROA % too high?
Cryofocus Medtech (Shanghai) Co's current ROA % is -19.42%. Based on the distribution chart, Cryofocus Medtech (Shanghai) Co ranks #636 out of 851 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Cryofocus Medtech (Shanghai) Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryofocus Medtech (Shanghai) Co's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cryofocus Medtech (Shanghai) Co ranks #636 out of 851 companies for ROA %. This places Cryofocus Medtech (Shanghai) Co in the lower half of its industry. The industry median ROA % is 0.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.76, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Cryofocus Medtech (Shanghai) Co and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryofocus Medtech (Shanghai) Co's current ROA % is -19.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryofocus Medtech (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Cryofocus Medtech (Shanghai) Co (HKSE:06922) is currently considered Possible Value Trap. The stock's GF Value™ is HK$21.01, compared to a current price of HK$2.79 — trading 86.7% below its estimated fair value. The current ROA % is -19.42%. Cryofocus Medtech (Shanghai) Co's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Cryofocus Medtech (Shanghai) Co (HKSE:06922), the current ROA % is -19.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryofocus Medtech (Shanghai) Co (HKSE:06922) Overvalued in 2026?
Based on GuruFocus' analysis, Cryofocus Medtech (Shanghai) Co stock appears to be undervalued.
The current stock price of HK$2.79 is trading 86.7% below its estimated GF Value™ of HK$21.01.
GuruFocus considers Cryofocus Medtech (Shanghai) Co to be Possible Value Trap.
Key valuation signals for HKSE:06922:
ROA %: -19.42%
GF Value™: HK$21.01 vs. price of HK$2.79 (86.7% below fair value)
No single metric tells the full story. See the HKSE:06922 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryofocus Medtech (Shanghai) Co Ltd is a medical device company engaged in the research and development, manufacture, and sale of cryoablation minimally invasive interventional treatment technology and related medical products. The company uses liquid nitrogen as the main cryogenic source for cryotherapy systems by leveraging liquid nitrogen cryoablation technology and flexible catheter technology. The products offered by the company include: Bladder Cryoablation System, Pulmonary Nodule Localization Needle, and Endoscopic Clip for Anastomosis, among others. Geographically, the company's revenue is generated from the sale of medical consumables and devices in the Chinese Mainland.
61GF Score
Get the complete analysis for HKSE:06922
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06922 has been successfully added to your 
